Cognition Therapeutics Receives Fast Track Designation From U.S. FDA For First-In-Class Alzheimer’s Candidate, CT1812 Clinical Leader By John Harbison|2017-10-16T12:23:11-08:00October 16, 2017|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Cognition Therapeutics Receives Fast Track Designation From U.S. FDA For First-In-Class Alzheimer’s Candidate, CT1812 Share This Story, Choose Your Platform! FacebookTwitterRedditLinkedInWhatsAppTumblrPinterestVkXingEmail About the Author: John Harbison Related Posts
